TABLE 2.
Summary of chemotherapy regimens administered before and after treatment with PD‐1 inhibitors
| Patient | Chemo‐refractory a | Last chemo before anti‐PD1 | Disease response | PD‐1 inhibitors (no. of cycles) | Chemo post anti‐PD1 | No. of cycles | Disease response |
|---|---|---|---|---|---|---|---|
| 1 | NO | BRENTUXIMAB | PD | 10 | BEACOPP | 2 | CR |
| 2 | YES | BENDAMUSTINE | PD | 24 | BEACOPP | 2 | CR |
| 3 | YES | BRENTUXIMAB+BENDA | PD | 32 | BEACOPP | 2 | PR |
| 4 | YES | FEAM + ASCT | PD | 10 | BEACOPP+RT | 4 | SD |
| 5 | YES | FEAM + ASCT | SD | 41 | BEGEV | 4 | CR |
| 6 | NO | BRENTUXIMAB | PD | 53 | IGEV | 2 | CR |
| 7 | YES | FEAM + ASCT | SD | 55 | BEGEV | 4 | CR |
| 8 | YES | BRENTUXIMAB | PD | 37 | BEGEV | 4 | CR |
| 9 | YES | RMACOBP | PD | 15 | BRENTUXIMAB | 5 | CR |
| 10 | YES | DHAP | PD | 23 | L‐PAM + ASCT | / | CR |
| 11 | YES | BRENTUXIMAB | PD | 74 | BEGEV | 1 | CR |
| 12 | YES | BEGEV | PD | 12 | BEGEV | 2 | CR |
| 13 | YES | BRENTUXIMAB | PD | 72 | BEGEV | 4 | CR |
| 14 | YES | BEGEV | PD | 12 | BEGEV | 1 | CR |
| 15 | YES | GEM + VNR | PD | 31 | BEGEV | 7 | CR |
| 16 | YES | GVD | PR | 8 | BEGEV | 4 | CR |
| 17 | NA | BRENTUXIMAB | PD | 3 | GEM | 4 | PD |
| 18 | YES | BRENTUXIMAB | PD | 17 | HD‐CTX + FEAM + ASCT | / | CR |
| 19 | YES | GDP | PD | 12 | FEAM + ASCT | / | CR |
| 20 | YES | FEAM + ASCT | PD | 12 | HD‐VP‐16 | / | PR |
| 21 | YES | BRENTUXIMAB | PD | 10 | GEM | 2 | PR |
| 22 | YES | BRENTUXIMAB | PD | 8 | L‐PAM+ ASCT | / | CR |
| 23 | YES | BRENTUXIMAB | PD | 10 | L‐PAM+ ASCT | / | CR |
| 24 | YES | BRENTUXIMAB + BENDA | PD | 7 | L‐PAM+ ASCT+RT | / | CR |
| 25 | YES | BRENTUXIMAB | PD | 10 | BENDA | 3 | CR |
| 26 | YES | BRENTUXIMAB | SD | 29 | BEGEV | 2 | CR |
| 27 | YES | BRENTUXIMAB | PD | 13 | BEGEV | 3 | CR |
| 28 | YES | CTX | PD | 12 | OxDHA + RT | 1 | CR |
BENDA, bendamustine; ASCT, autologous stem cell transplantation; CTX, cyclophosphamide; RT, radiation therapy; HD, high‐dose.
a
Refractory to 1st line therapy.